Inhaled Corticosteroid Exposure in Hospitalized Infants with Bronchopulmonary Dysplasia

Overview

Journal Am J Perinatol

Specialty Gynecology & Obstetrics

Date 2022 May 6

PMID 35523409

Authors

Chelsey Leiting

Ellen Kerns

Joshua C Euteneuer

Russell J McCulloh

Eric S Peeples

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this paper was to determine inhaled corticosteroid (IC) use in infants with bronchopulmonary dysplasia (BPD), define the interhospital variation of IC administration to infants with BPD, and compare clinical, demographic, and hospital factors associated with IC use.

Study Design: Using the Pediatric Health Information System database, a retrospective multicenter cohort of 4,551 infants born at <32 weeks of gestation with developing BPD was studied. The clinical, demographic, and hospital characteristics of infants exposed and not exposed to ICs were compared.

Results: IC use varied markedly between hospitals, ranging from 0 to 66% of infants with BPD exposed to ICs. Increased annual BPD census was not associated with IC use. In total, 25% (1,144 out of 4,551) of patients with BPD and 43% (536 out of 1,244) of those with severe BPD received ICs. Increased IC exposure was associated with lower birth weight and gestational age, days on respiratory support, need for positive pressure ventilation at 36-week postmenstrual age, need for tracheostomy, and increased use of systemic steroids, bronchodilators, and diuretics.

Conclusion: IC exposure is common in infants with BPD, with substantial interhospital variability. IC use was associated with more severe disease. Hospital experience did not account for the wide variability in IC use by the hospital. Further research into the effects of ICs use is urgently needed to help guide their use in this vulnerable population.

Key Points: · The risks and benefits of IC use in infants with BPD are incompletely understood.. · IC use is common in infants with BPD (25%) and severe BPD (43%) varies widely by hospital (0-66% of patients with BPD received an IC).. · Hospital experience did not account for the wide interhospital variation in IC use..

References

Shinwell E, Portnov I, Meerpohl J, Karen T, Bassler D . Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis. Pediatrics. 2016; 138(6). DOI: 10.1542/peds.2016-2511. View

Greenberg J, Poindexter B, Shaw P, Bellamy S, Keller R, Moore P . Respiratory medication use in extremely premature (<29 weeks) infants during initial NICU hospitalization: Results from the prematurity and respiratory outcomes program. Pediatr Pulmonol. 2019; 55(2):360-368. DOI: 10.1002/ppul.24592. View

Kelly H, Van Natta M, Covar R, Tonascia J, Green R, Strunk R . Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics. 2008; 122(1):e53-61. PMC: 2928657. DOI: 10.1542/peds.2007-3381. View

Nelin L, Logan J . The use of inhaled corticosteroids in chronically ventilated preterm infants. Semin Fetal Neonatal Med. 2017; 22(5):296-301. DOI: 10.1016/j.siny.2017.07.005. View

Ryan R, Keller R, Poindexter B, DAngio C, Shaw P, Bellamy S . Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium. J Pediatr. 2019; 208:148-155.e3. PMC: 6486865. DOI: 10.1016/j.jpeds.2018.12.009. View

Euteneuer J, Kerns E, Leiting C, McCulloh R, Peeples E . Inhaled bronchodilator exposure in the management of bronchopulmonary dysplasia in hospitalized infants. J Perinatol. 2020; 41(1):53-61. PMC: 7404081. DOI: 10.1038/s41372-020-0760-8. View

Cole C, Shah B, Abbasi S, Demissie S, MacKinnon B, Colton T . Adrenal function in premature infants during inhaled beclomethasone therapy. J Pediatr. 1999; 135(1):65-70. DOI: 10.1016/s0022-3476(99)70329-x. View

Ng P, Fok T, Wong G, Lam C, Lee C, Wong M . Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab. 1998; 83(7):2390-3. DOI: 10.1210/jcem.83.7.4947. View

Venkataraman R, Kamaluddeen M, Hasan S, Robertson H, Lodha A . Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Pediatr Pulmonol. 2017; 52(7):968-975. DOI: 10.1002/ppul.23680. View

10.

Jensen E, Schmidt B . Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014; 100(3):145-57. PMC: 8604158. DOI: 10.1002/bdra.23235. View

11.

Bassler D, Plavka R, Shinwell E, Hallman M, Jarreau P, Carnielli V . Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med. 2015; 373(16):1497-506. DOI: 10.1056/NEJMoa1501917. View

12.

Guaman M, Gien J, Baker C, Zhang H, Austin E, Collaco J . Point Prevalence, Clinical Characteristics, and Treatment Variation for Infants with Severe Bronchopulmonary Dysplasia. Am J Perinatol. 2015; 32(10):960-7. PMC: 4617756. DOI: 10.1055/s-0035-1547326. View

13.

Clark R, Bloom B, Spitzer A, Gerstmann D . Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006; 117(6):1979-87. DOI: 10.1542/peds.2005-1707. View

14.

Bassler D, Shinwell E, Hallman M, Jarreau P, Plavka R, Carnielli V . Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. N Engl J Med. 2018; 378(2):148-157. DOI: 10.1056/NEJMoa1708831. View

15.

Slaughter J, Stenger M, Reagan P, Jadcherla S . Utilization of inhaled corticosteroids for infants with bronchopulmonary dysplasia. PLoS One. 2014; 9(9):e106838. PMC: 4156388. DOI: 10.1371/journal.pone.0106838. View

16.

Htun Z, Schulz E, Desai R, Marasch J, McPherson C, Mastrandrea L . Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia. J Perinatol. 2021; 41(8):1783-1796. PMC: 8133053. DOI: 10.1038/s41372-021-01083-w. View

17.

Higgins R, Jobe A, Koso-Thomas M, Bancalari E, Viscardi R, Hartert T . Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatr. 2018; 197:300-308. PMC: 5970962. DOI: 10.1016/j.jpeds.2018.01.043. View

18.

Yeh T, Chen C, Wu S, Husan Z, Li T, Hsieh W . Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2015; 193(1):86-95. DOI: 10.1164/rccm.201505-0861OC. View

19.

Shah S, Ohlsson A, Halliday H, Shah V . Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2017; 10:CD002058. PMC: 6485718. DOI: 10.1002/14651858.CD002058.pub3. View

20.

Kelly H, Sternberg A, Lescher R, Fuhlbrigge A, Williams P, Zeiger R . Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012; 367(10):904-12. PMC: 3517799. DOI: 10.1056/NEJMoa1203229. View